Mogamulizumab - Kyowa Hakko Kirin

Drug Profile

Mogamulizumab - Kyowa Hakko Kirin

Alternative Names: AMG-761; KW-0761; Mogamulizumab-kpkc; Poteligeo

Latest Information Update: 06 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyowa Hakko
  • Developer Amgen; Bristol-Myers Squibb; Kyowa Hakko Kirin; Ono Pharmaceutical
  • Class Antiasthmatics; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Peripheral T-cell lymphoma; Adult T-cell leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adult T-cell leukaemia-lymphoma; Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
  • Phase III Spinal cord disorders
  • Phase I/II Solid tumours
  • Research Mycosis fungoides; Sezary syndrome
  • No development reported Non-small cell lung cancer
  • Discontinued Asthma; Hypersensitivity

Most Recent Events

  • 30 Sep 2018 Discontinued - Phase-I for Solid tumours in Japan (IV) (Kyowa pipeline, November 2018)
  • 28 Sep 2018 Efficacy data from the phase III MAVORIC trial in Cutaneous T-cell lymphoma (CTCL) released by Kyowa Kirin
  • 21 Sep 2018 Kyowa Hakko Kirin expects European Commissions (EC) final decision on the grant of marketing authorisation by end of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top